This page shows what was measured, who it was measured in, and what that does not settle.
What Acalabrutinib does in the body
CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
From the FDA-approved label: Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK). Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, acalabrutinib inhibited BTK‑mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and tumor growth in mouse xenograft models.
Why people take it. CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · I42748ELQW · read 2026-08-29
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 182 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Healthy ageing
all cause mortality
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
… Waiting for a reviewer
1 registered study measure of this kind. No reviewed result yet.
∅ Nothing in the sources checked
No registered study lists a performance measure for this goal.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
All-cause mortality
✗ The study did not show it
Who was studied
NCT05024006
How many people
1314
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR)
✗ The study did not show it
Who was studied
NCT06136559
How many people
1200
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
To evaluate the efficacy of acalabrutinib with venetoclax (Arm A) compared to chemoimmunotherapy fludarabine/cyclophosphamide/rituximab [FCR] or bendamustine/rituximab [BR] (Arm C): PFS
✗ The study did not show it
Who was studied
NCT03836261
How many people
984
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Maximum Tolerated Dose (MTD)
✗ The study did not show it
Who was studied
NCT03740529
How many people
803
Study design
Phase 1/Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2
✗ The study did not show it
Who was studied
NCT02972840
How many people
635
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B
✗ The study did not show it
Who was studied
NCT04529772
How many people
611
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.7 registered measures of this kind. 2 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
maximum observed plasma concentration
Meaningful
Things that change how a life goes, not only a number.
event free survival
complete remission rate
all cause mortality
progression free survival
real world progression free survival
progress free survival
progression free survival by irc
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (32)
incidence of treatment emergent adverse events
part 1 incidence of treatment emergent adverse events
treatment emergent adverse events
grade 3 4 adverse events
grade 5 adverse events
any study drug related ae
grade 3 4 study drug related ae
grade 5 study drug related ae
any sae
grade 3 4 any sae
grade 5 any sae
any study drug related sae
overall response
overall response rate
experiencing dose limiting toxicities
complete response
response rate
adverse events
rate of undetected minimal residual disease
objective response rate
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). ( 1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and efficacy of CALQUENCE in pediatric patients have not been established.”
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-30
On older people, the label states: “CLL and Previously Treated MCL Of the 1,758 CALQUENCE-treated patients with B-cell malignancies (excluding previously untreated MCL) in clinical trials, 1,074 (61%) were 65 years of age or older, and 341 (19%) were 75 years of age or older.”
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on findings in animals, CALQUENCE may cause fetal harm and dystocia when administered to a pregnant woman.”
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary No data are available regarding the presence of acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production.”
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-30
On people with reduced liver function, the label states: “Avoid use of CALQUENCE in patients with severe hepatic impairment (Child-Pugh class C).”
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S4.
No source is stored against this line.
What is in the pack
Sold as capsule, tablet, tablet, film coated, capsule, gelatin coated, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Acalabrutinib appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 129 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
12 products list this as an active ingredient in the United States drug directory. 12 of them contain it and nothing else.
FDA National Drug Code directory · 17228-4512 · read 2026-08-29
They are sold as capsule, gelatin coated, powder and tablet, film coated, taken oral.
FDA National Drug Code directory · 17228-4512 · read 2026-08-29
The regulator's established pharmacologic class for it is kinase inhibitor [epc] and tyrosine kinase inhibitors [moa].
FDA National Drug Code directory · 17228-4512 · read 2026-08-29
2 published labels name it as an active ingredient. 2 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-29
CALQUENCE is oral at 3 DOSAGE FORMS AND STRENGTHS Tablets:100 mg acalabrutinib, orange, oval, film-coated, biconvex, debossed with ‘ACA 100’ on one side and plain on the other., recorded as fda label in effect 2026-02-19 in the United States.
US prescribing information · b1409184-3267-4d8c-8f17-4e01f69828b1 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Acalabrutinib studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Acalabrutinib are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
2 documents were read for this substance.
RNAWiki source record
2 of them state the same bioavailability, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
I42748ELQW
RxNorm concept
2607734
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
4 approved applications cover products containing this substance. The earliest was NDA210259, approved 20171031 to ASTRAZENECA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (12)
Q2
What did Acalabrutinib's largest trial (15000 people) and its longest (14 years) measure?
15000 people in Acalabrutinib's largest registered study, 14 years in its longest registered window, measuring All cause Mortality. ClinicalTrials.gov · 2026-09-01
89 phase2, 43 phase1, 21 phase3, 4 na or unstated, 2 na, 2 phase4, 1 early phase1; NCT02180711; 2028-12-11; no ageing endpoint recorded. Last human test completed 2026, NCT05517265.
Interpretation These counts include studies where Acalabrutinib was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
89
phase1
43
phase3
21
na or unstated
4
na
2
phase4
2
2 more recorded rows
early phase1
1
Last recorded human testNCT05517265
2026-03-20
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Acalabrutinib shown lifespan?
futility/efficacy (1), accrual/recruitment (2), funding/business (2), sponsor decision unspecified (4) and other (3): Acalabrutinib's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Sponsor Decision"; 12 of 142 registered studies
Show the evidence
Trial
NCT02570711
terminated; "Sponsor Decision"
NCT03205046
terminated; "Sponsor's decision not to pursue further development of the combination in DLBCL"
NCT03492125
terminated; "The study is terminated due to major protocol revisions. A new study in CLL patients is planned."
NCT04016805
terminated; "Strategic/Business decision"
NCT04189952
terminated; "Investigator Decision"
NCT04337827
terminated; "Slow accrual"
6 further recorded trials
NCT04497948
terminated; "Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints. Based on this higher management made the decision to prematurely terminate the D822FC00005 PK…"
withdrawn; "Bayer is no longer funding due to lack of accrual"
NCT04836832
withdrawn; "PI decision"
NCT05205252
withdrawn; "Epizyme Inc. has revised the Tazemetostat development strategy and made the decision to terminate the hematological malignancies basket trial."
NCT06839872
withdrawn; "AstraZeneca has made the decision to cancel the trial."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Acalabrutinib used Acalabrutinib 100 MG Oral Capsule — over how long?
1 recorded entry; human; also "Acalabrutinib 100 MG Oral Capsule"
Show the evidence
humanNCT04178798
Acalabrutinib 100 MG Oral Capsule
recorded 2026-09-01 · last checked 2026-09-04
Q6
Which of adverse events, adverse events and serious adverse events and all cause mortality did Acalabrutinib's trials measure?
adverse events, adverse events and serious adverse events and all cause mortality lead 40 outcome terms across Acalabrutinib's trials. ClinicalTrials.gov · 2026-09-01
grade 3 4 adverse events, grade 5 adverse events, any study drug related ae, grade 3 4 study drug related ae, grade 5 study drug related ae and any sae follow.
Show the evidence
incidence of treatment emergent adverse events
1
part 1 incidence of treatment emergent adverse events
1
treatment emergent adverse events
1
grade 3 4 adverse events
1
grade 5 adverse events
1
any study drug related ae
1
14 more recorded rows
grade 3 4 study drug related ae
1
grade 5 study drug related ae
1
any sae
1
grade 3 4 any sae
1
grade 5 any sae
1
any study drug related sae
1
overall response
1
overall response rate
1
experiencing dose limiting toxicities
1
event free survival
1
complete response
1
response rate
1
adverse events
1
rate of undetected minimal residual disease
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Acalabrutinib's 87 ongoing trials reports first?
Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1; Incidence of Treatment-Emergent Adverse Events; latest 2033-03-23
Show the evidence
Trial
NCT02029443
"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia"; n 306; "Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1"; 2027-06-09
NCT02157324
"Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia"; n 12; "Incidence of Treatment-Emergent Adverse Events"; 2026-04-01
NCT02180711
"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma"; n 113; "Part 1: Incidence of Treatment-emergent Adverse Events."; 2028-12-11
NCT02180724
"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia"; n 107; "Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria"; 2026-12-31
NCT02475681
"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL"; n 535; "Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B"; 2026-09-15
NCT02477696
"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)"; n 533; "Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment"; 2028-01-03
14 further recorded trials
NCT02586857
"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)"; n 24; "Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria."; 2026-04-01
NCT02717611
"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy"; n 60; "The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)"; 2026-06-06
NCT02970318
"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL"; n 310; "Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment"; 2027-10-01
NCT02972840
"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL"; n 635; "Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2"; 2027-02-15
NCT03128879
"Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL"; n 59; "The primary endpoint will be the rate of MRD-negativity in the bone marrow, using an assay method with at least 0.01% sensitivity after 12 cycles of combination therapy. One cycle is 4 weeks of treatment."; 2027-05-31
NCT03328273
"A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)"; n 12; "Number of participants experiencing dose-limiting toxicities"; 2026-08-26
NCT03516617
"Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"; n 120; "Rate of minimal residual disease (MRD)-negative complete response (Arm A and Arm B)"; 2030-10-16
NCT03571568
"A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL"; n 140; "Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab and/or acalabrutinib"; 2026-09-30
NCT03580928
"Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL"; n 72; "Rate of Bone Marrow (BM) Minimal Residual Disease (MRD) Negative Complete Response (CR) After 15 Cycles"; 2027-12-31
NCT03836261
"Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL"; n 984; "To evaluate the efficacy of acalabrutinib with venetoclax (Arm A) compared to chemoimmunotherapy fludarabine/cyclophosphamide/rituximab [FCR] or bendamustine/rituximab [BR] (Arm C): PFS"; 2027-01-31
NCT03863184
"Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL"; n 37; "Peripheral Blood Minimum Residual Disease (MRD)-Negative Complete Response (CR) Rate of the Combination of Acalabrutinib + Lenalidomide + Rituximab at the Conclusion of 12 Cycles of Induction Therapy"; 2028-05-30
NCT03868722
"Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment"; n 212; "Grade 3-Infection-free survival"; 2030-07-31
NCT03899337
"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome"; n 72; "Randomised Component - Progression free survival (PFS)"; 2028-07-31
NCT03932331
"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies"; n 105; "Phase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)"; 2026-06-24
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Acalabrutinib could settle lifespan?
NCT02475681 measures Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B, reading out 2026-09-15.
20 open trials; n 535; "Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL"
Show the evidence
Trial
NCT02475681
"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL"; n 535; "Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B"; 2026-09-15
NCT05950997
"A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL"; n 89; "Progression-free survival rate at 24 months"; 2026-09-30
NCT04075292
"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia"; n 155; "Progression Free Survival (PFS) Assessed by BICR"; 2027-01-01
NCT04722172
"A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL"; n 55; "progression-free survival (PFS)"; 2027-02
NCT02972840
"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL"; n 635; "Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2"; 2027-02-15
NCT04529772
"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)"; n 611; "Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B"; 2027-02-22
14 further recorded trials
NCT05388006
"Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"; n 27; "Progression free survival"; 2027-02-22
NCT05557695
"Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom"; n 350; "Real-world progression free survival (rwPFS)"; 2027-04-01
NCT02970318
"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL"; n 310; "Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment"; 2027-10-01
NCT06441097
"Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL"; n 152; "Progression-free survival（by IRC）"; 2027-12-31
NCT02477696
"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)"; n 533; "Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment"; 2028-01-03
NCT04662255
"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)"; n 500; "To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)"; 2028-04
NCT05197192
"A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL"; n 202; "Progression-free survival (PFS)"; 2028-05
NCT03899337
"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome"; n 72; "Randomised Component - Progression free survival (PFS)"; 2028-07-31
NCT06319456
"A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL."; n 344; "Progress Free Survival (PFS)"; 2028-08
NCT05057494
"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"; n 607; "Progression-free Survival (PFS)"; 2029-04-10
NCT03868722
"Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment"; n 212; "Grade 3-Infection-free survival"; 2030-07-31
NCT04604067
"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial."; n 260; "Cohorts A, C and D: Progression free survival (PFS) according to the Lugano criteria"; 2030-12
NCT07277231
"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia"; n 500; "Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)"; 2031-11
NCT07377578
"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma"; n 394; "Progression-free survival (PFS) assessed by IRC"; 2033-01-30
Q9
Which 16 trials of Acalabrutinib posted no result?
Posted no result
16 of 16 completed trials
Registrations
NCT04901923, NCT04914936, NCT04867941, NCT04876807, NCT04898101 and NCT04867980, and 10 more
Completion dates
oldest 2014-05-22; newest 2023-09-26
Show the evidence
Trial
NCT04901923
2014-05-22
NCT04914936
2014-10-16
NCT04867941
2015-02-02
NCT04876807
2016-03-15
NCT04898101
2016-04-13
NCT04867980
2016-05-09
10 further recorded trials
NCT04905043
2016-07-11
NCT05140096
2020-04-15
NCT04489797
2020-08-28
NCT04564040
2020-12-11
NCT03527147
2021-03-31
NCT05024006
2021-04-17
NCT04768985
2021-05-10
NCT04094142
2022-05-15
NCT03571308
2023-08-31
NCT03787264
2023-09-26
Q10
At the median, Acalabrutinib's trials enrolled 50.5 people — anything larger?
Median enrolment
50.5
Largest enrolment
15000
Registered trials counted
142
Q11
What do 129 spontaneous reports say about Acalabrutinib — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Acalabrutinib appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 129 reaction mentions were counted: malignant neoplasm progression 24; atrial fibrillation 20; febrile neutropenia 17; disease progression 15. open-targets-adr · CHEMBL3707348 · 2026-06-24
Show the evidence
malignant neoplasm progression
24
atrial fibrillation
20
febrile neutropenia
17
disease progression
15
drug resistance
15
covid-19
12
4 more recorded rows
leukocytosis
9
myelodysplastic syndrome
6
tumour lysis syndrome
6
lymphocytosis
5
recorded 2026-06-24 · last checked 2026-09-04
Q12
Acalabrutinib and CYP3A4, BCRP and CYP1A2: shared by which compounds?
CYP3A4, BCRP and CYP1A2 appear in Acalabrutinib's recorded interaction sentences, 18 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2
pharmacokinetics
Acalabrutinib is an inducer of CYP1A2, CYP2B6, and CYP3A4.
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5.
CYP2B6
pharmacokinetics
Acalabrutinib is an inducer of CYP1A2, CYP2B6, and CYP3A4.
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5.
CYP2C19
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5.
CYP2C8
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5.
CYP2C9
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5.
CYP2D6
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5.
CYP3A4
pharmacokinetics
Acalabrutinib is an inducer of CYP1A2, CYP2B6, and CYP3A4.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inducer of CYP3A4.
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6.
pharmacokinetics
Acalabrutinib’s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5.
recorded 2026-08-30 · last checked 2026-09-04
Q13
What is recorded about Acalabrutinib and IGF-1?
"In order to test for potential off-target effects, second generation BTK inhibitor Acalabrutinib with greater BTK selectivity and lower cardiovascular toxicity was tested for IGF1-mediated activation of intracellular Ca handling." — where Acalabrutinib and IGF-1 appear together. Europe PMC · pathway abstract search · 2023-08-15
IGF-1; PMID 37655217
Show the evidence
IGF-1
PMID 37655217
"In order to test for potential off-target effects, second generation BTK inhibitor Acalabrutinib with greater BTK selectivity and lower cardiovascular toxicity was tested for IGF1-mediated activation of intracellular Ca handling."
PMID 37655217
"Acalabrutinib induced similar effects on Ca handling in IGF-1 treated cultured myocytes as Ibrutinib in regard to decreased Ca transient amplitude and slowed Ca transient decay, hence implying a functional class effect of BTK inhibitors in cardiac myocytes."
recorded 2023-08-15 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.